New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

Area of Science:

• Oncology
• Gastroenterology
• Endocrinology

Background:

• Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms with varying clinical presentations.
• Functional GEP-NETs can secrete hormones, leading to syndromes like carcinoid syndrome (flushing, diarrhea, bronchospasm, cardiac issues).
• Classification relies on primary site, functionality, and histology, guiding treatment decisions.

Purpose of the Study:

• To outline the classification and current treatment strategies for GEP-NETs.
• To highlight therapeutic options for unresectable GEP-NETs, including medical and localized approaches.
• To discuss specific treatments for pancreatic neuroendocrine tumors (PNETs).

Main Methods:

• Review of current treatment guidelines and therapeutic options for GEP-NETs.
• Discussion of first-line treatments such as somatostatin analogs (octreotide LAR, lanreotide).
• Exploration of additional therapies for PNETs (everolimus, sunitinib, chemotherapy) and palliative local treatments.

Main Results:

• Somatostatin analogs are a standard first-line treatment for unresectable GEP-NETs, managing symptoms like diarrhea and flushing.
• Everolimus and sunitinib show antitumor activity in pancreatic NETs.
• Localized therapies (surgery, embolization, ablation) offer palliative care for liver metastases.

Conclusions:

• Treatment for GEP-NETs is individualized based on resectability, metastatic extent, and symptoms.
• Somatostatin analogs, targeted agents, chemotherapy, and local therapies form a multi-modal approach to GEP-NET management.
• Ongoing research and drug approvals continue to expand treatment options for these rare tumors.